Drugs / High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04374565 | May 2020 → Mar 2021 | pneumonia, severe acute respiratory syndrome | University of Virginia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04374565 ↗ |
| Modality | Protein / enzyme biologic | “The only antibody formulation that is available for emergent use is that found in convalescent plasma.” NCT04374565 ↗ |